Oncology Study of Endothelial Glycocalyx Integrity Using Microvascular Health Solutions GlycoCheck Test Device


Study of the endothelial glycocalyx in oncology patients

BioRegenx logo


GlycoCheck test


Glycocalyx Endothelial Integrity Patient Oncology Study Using Microvascular Health Solutions GlycoCheck Medical Test Device

CHATTANOOGA, TN, USA, Aug. 2, 2022 /EINPresswire.com/ — Microvascular Health Solutions (MVHS), a subsidiary of BioRegenx, announces that a new peer-reviewed study using GlycoCheck, an exclusively distributed medical testing device worldwide by MVHS, has been released. The study, published by the International Journal of Cardiology, is titled Endothelial Glycocalyx Integrity in Oncology Patients. The study was conducted at the National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece, and led by Professor Ignatios Ikonomidis.

Cancer is associated with early changes in the cardiovascular (CV) system before overt cardiotoxicity. Endothelial dysfunction is induced by chemotherapy regimens, but prior to this study, there were no data on endothelial glycocalyx in cancer patients.

Sixty-four cancer patients (65.6% with solid tumors and 34.4% with hematological malignancies) and 32 controls from the cardiology outpatient clinic were included in the study.

The PBR 5-25 was significantly increased in cancer patients compared to controls (2.11 ± 0.36 vs 1.97 ± 0.21, p = 0.025). Alteration in endothelial glycocalyx thickness was independent of traditional CV risk factors and cancer therapy, but proportional to disease stage (r = 0.337, p = 0.044).


The study concludes that endothelial function as assessed by endothelial glycocalyx thickness is significantly impaired in cancer patients without overt cardiotoxicity. This implies that the PBR 5-25 could be useful for the early assessment of microvascular and endothelial cancer toxicity. Read the full study here.

About BioRegenx

BioRegenx, Inc., (BioRegenx.com), a holding company, is the parent company of three wholly owned subsidiaries, Microvascular Health Solutions, LLC, My Body Rx, LLC and NuLife Sciences, Inc. BioRegenx and its subsidiaries combine the patented intellectual property owned by the revolutionary medical test device GlycoCheck, the patented nutraceutical Endocalyx Pro, other synergistic dietary supplements sold under the My Body Rx brand, and a customer base of healthcare professionals and brand partners throughout the North America.

Safe Harbor

This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding potential sales, the success of the company’s business , as well as statements that include the word believe or similar expressions. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioRegenx, Inc. to differ materially from those implied or expressed by these forward-looking statements. This press release applies as of the date first listed above, and BioRegenx, Inc. assumes no responsibility to update the information included herein for events after the date of the press release. present. Actual results could differ materially from those anticipated due to factors such as lack of capital, rapid product development, inability to deliver products when ordered, inability of potential customers to pay for products ordered and the political and economic risks inherent in international trade.

William resides
+1 800 – 398 – 9842
[email protected]


About Author

Comments are closed.